Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Melanoma NGS routine care

PROVIDER: PRJNA647798 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12284800.fastq.gz	Fastqsanger.gz
	SRR12284900.fastq.gz	Fastqsanger.gz
	SRR12285000.fastq.gz	Fastqsanger.gz
	SRR12285100.fastq.gz	Fastqsanger.gz
	SRR12284801.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 421

Similar Datasets

Whole blood transciptome analysis in severe Covid-19 patients and healthy donors

Project description:The identification of COVID-19 patients with high-risk of severe disease is a challenge in routine care. We performed blood RNA-seq gene expression analyses in severe hospitalized patients compared to healthy donors. Supervised and unsupervised analyses revealed a high abundance of CD177, a specific neutrophil activation marker, contributing to the clustering of severe patients. Gene abundance correlated with high serum levels of CD177 in severe patients. These results highlight neutrophil activation as a hallmark of severe disease and CD177 assessment as a reliable prognostic marker for routine care.

2021-05-27 | GSE171110 | GEO

Analysis of circulating miRNAs altered in the acute respiratory distress syndrome related to SARS-CoV-2 infection

Project description:Circulating miRNAs in patients who underwent ARDS and needed mechanical ventilation were analyzed by next generation sequencing (NGS) in comparison with patients who had COVID-19 poor symptoms but without intensive care unit requirement.

2022-04-12 | GSE182183 | GEO

Next Generation Sequencing of Transcriptomes of Cutaneous Melanocytes and Metastatic Melanoma Cell Lines (miRNA-Seq)

Project description:The goal of the study is to compare NGS-derived transcriptome (miRNA-seq) profiles of melanocytes and metastatic melanoma cells and identify microRNAs involved in melanomagenesis

2019-01-16 | GSE109244 | GEO

High-throughput tissue dissection and cell purification with digital cytometry [healthy adults]

Project description:Tissue composition is a major determinant of phenotypic variation and a key factor influencing disease outcomes. Although scRNA-Seq has emerged as a powerful technique for characterizing cellular heterogeneity, it is currently impractical for large sample cohorts and cannot be applied to fixed specimens collected as part of routine clinical care. To overcome these challenges, we extended Cell type Identification By Estimating Relative Subsets Of RNA Transcripts (CIBERSORT) into a new platform for in silico cytometry. Our approach enables the simultaneous inference of cell type abundance and cell type-specific gene expression profiles (GEPs) from bulk tissue transcriptomes. The utility of this integrated framework, called CIBERSORTx, is demonstrated in multiple tumor types, including melanoma, where single cell reference profiles are used to dissect primary clinical specimens, revealing cell type-specific signatures of driver mutations and immunotherapy response. We anticipate that digital cytometry will augment single cell profiling efforts, enabling cost-effective, high throughput tissue characterization without the need for antibodies, disaggregation, or viable cells.

2019-05-06 | GSE127813 | GEO

High-throughput tissue dissection and cell purification with digital cytometry [scRNA-Seq]

2019-05-06 | GSE127471 | GEO

High-throughput tissue dissection and cell purification with digital cytometry [Affymetrix]

2019-05-06 | GSE127462 | GEO

Clinical Utility of Targeted Next-Generation Sequencing Assay to Detect Copy Number Variants in Myeloid Malignancies: Is It Ready for Prime Time?

Project description:Genetic abnormalities including copy number variants (CNVs, such as gains and losses), and gene mutations are important for diagnosis and treatment of myeloid malignances. In a routine clinical setting, somatic gene mutations are detected by targeted next generation sequencing (NGS), but CNVs are commonly detected by conventional chromosome analysis and fluorescence in situ hybridization (FISH). The aim of this proof-of-principle study was to investigate the feasibility of using a targeted NGS assay to simultaneously detect not only somatic mutations, but also CNVs. Here, we sequenced 406 consecutive patients with myeloid malignancies and performed a head-to-head comparison with the results from conventional clinical assays including conventional chromosome analysis and myeloid FISH to detect CNVs. The targeted NGS assay revealed all 120 CNVs detected by myeloid FISH panel including monosomy 5/5q deletions, monosomy 7/7q deletions, trisomy 8, and 20q deletions. Furthermore, the targeted NGS assay also detected 605 CNVs outsides targeted regions of the myeloid FISH panel, which were revealed by conventional cytogenetic testing. The targeted NGS assay achieved 100% concordance with the myeloid FISH for detection of these common myeloid CNVs, with a high clinical sensitivity (> 99%) and specificity (>99%). The lower limit of detection by the myeloid FISH and the targeted NGS assay was similar and was generally 5% variant allele fraction for DNA. This proof-of-principle study demonstrated that the targeted NGS assay can simultaneously detect both common myeloid CNVs and somatic mutations, which can provide more comprehensive genetic profiling for patients with myeloid malignancies using a single assay.

2021-01-29 | GSE165733 | GEO

geneplus-melanoma

Project description:next-generation sequencing (NGS) of Chinese patients with melanoma

2022-01-20 | PRJEB50175 | EVA

NGS-based pipeline for NIPGT-A

Project description:NGS-based pipeline for routine non-invasive pre-implantation genetic assessment in IVF

| PRJEB38821 | ENA

Next Generation Sequencing of Transcriptomes of Cutaneous Melanocytes and Metastatic Melanoma Cell Lines (mRNA-Seq)

Project description:The goal of the study is to compare NGS-derived transcriptome (mRNA-seq) profiles of melanocytes and metastatic melanoma cells and identify genes involved in melanomagenesis

2019-01-16 | GSE109245 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data